Statin treatment increases the sialic acid content of LDL in hypercholesterolemic patients

Atherosclerosis

Volumn 151, Issue 2, 2000, Pages 545-550

  Lindbohm, Nina ^a   Gylling, Helena ^a   Miettinen, Tatu E ^a   Miettinen, Tatu A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Apolipoprotein B; Hypercholesterolemia; LDL kinetics; Sialic acid; Statin

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIALIC ACID; SIMVASTATIN; STATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID STORAGE; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; SIALYLATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; PYRIDINES; SIMVASTATIN;

EID: 0033866738     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00425-6     Document Type: Article

References (33)

1. Swaminathan N., Aladjem F. The monosaccharide composition and sequence of the carbohydrate moiety of human serum low density lipoproteins. Biochemistry. 15:1976;1516-1522.
2. Filipovic I., Schwarzmann G., Mraz W., Wiegandt H., Buddecke E. Sialic-acid content of low-density lipoproteins controls their binding and uptake by cultured cells. Eur. J. Biochem. 93:1979;51-55.
3. Orekhov A.N., Tertov V.V., Mukhin D.N., Mikhailenko I.A. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem. Biophys. Res. Commun. 162:1989;206-211.
4. Sobenin I.A., Tertov V.V., Orekhov A.N., Smirnov V.N. Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells. Atherosclerosis. 89:1991;151-154.
5. Orekhov A.N., Tertov V.V., Mukhin D.N. Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis. 86:1991;153-161.
6. Tertov V.V., Sobenin I.A., Gabbasov Z.A., Popov E.G., Jaakkola O., Solakivi R., Nikkari T., Smirnov V.N., Orekhov A.N. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab. Invest. 67:1992;665-675.
7. Tertov V.V., Sobenin I.A., Orekhov A.N. Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation. Int. J. Tiss. Reac. 14:1992;155-162.
8. Orekhov A.N., Tertov V.V., Sobenin I.A., Smirnov V.N., Via D.P., Guevara J. Jr, Gotto A.M. Jr, Morrisett J.D. Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J. Lipid Res. 33:1992;805-817.
9. Ruelland A., Gallou G., Legras B., Paillard F., Cloarec L. LDL sialic acid content in patients with coronary artery disease. Clin. Chim. Acta. 221:1993;127-133.
10. Melajärvi N., Gylling H., Miettinen T.A. Sialic acids and the metabolism of low density lipoprotein. J. Lipid Res. 37:1996;1625-1631.
11. Lindbohm N., Gylling H., Miettinen T.E., Miettinen T.A. Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidemia and primary moderate hypercholesterolemia. Clin. Chim. Acta. 285:1999;69-84.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
13. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
14. Sacks F.M., Pfeffer M.A., Moyne L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Nash D.T., Wun C.-C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
15. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto Jr A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
17. Svennerholm L. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim. Biophys. Acta. 24:1957;604-611.
18. Miettinen T., Takki-Luukkainen I-T. Use of butyl acetate in determination of sialic acid. Acta Chem. Scand. 13:1959;856-858.
19. Lipid Research Clinics Program. Manual of Laboratory Operations. Lipids and Lipoprotein Analysis. National Institutes of Health. DHEW Publication No. (NIH) 75-628. Bethesda, MD 1974;1:51-59.
20. Gylling H., Vanhanen H., Miettinen T.A. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J. Lipid Res. 34:1993;59-67.
21. Knuts L-R, Rastas M., Haapala P. MicroNutrica, Version 1.0. 1991;Kansaneläkelaitos (National Pensions Institute), Helsinki.
22. McFarlane A.S. Efficient trace-labelling of proteins with iodine. Nature. 182:1958;53.
23. Bilheimer D.W., Eisenberg S., Levy R.I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260:1972;212-221.
24. 131I-labelled plasma proteins. Phys. Med. Biol. 2:1957;36-53.
25. Miettinen T.A. Cholesterol metabolism during ketokonazole treatment in man. J. Lipid Res. 29:1988;43-51.
26. Orekhov A.N., Tertov V.V., Sobenin I.A., Akhmedzhanov N.M., Pivovarova E.M. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int. J. Cardiol. 62:1997;S67-77.
27. Warren L. The thiobarbituric acid assay of sialic acids. J. Biol. Chem. 234:1959;1971-1975.
28. Ehnholm C., Garoff H., Renkonen O., Simons K. Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. Biochemistry. 11:1972;3229-3232.
29. Berglund L. Diet and drug therapy for lipoprotein (a). Curr. Opin. Lipidol. 6:1995;48-56.
30. La Belle M., Krauss R.M. Differences in carbohydrate content of low density lipoproteins associated with low density subclass patterns. J. Lipid. Res. 31:1990;1577-1588.
31. Lee Y.C., Townsend R.R., Hardy M.R., Lönngren J., Arnarp J., Haraldsson M., Lönn H. Binding of synthetic oligosaccharides to hepatic Gal/GalNac lectin. Dependence on fine structural features. J. Biol. Chem. 258:1983;199-202.
32. Grewal T., Bartlett A., Burgess J.W., Packer N.H., Stanley K.K. Desialylated LDL uptake in human and mouse macrophages can be mediated by a lectin receptor. Atherosclerosis. 121:1996;151-163.
33. Ozaki K., Lee R.T., Lee Y.C., Kawasaki T. The differences in structural specificity for recognition and binding between asialoglycoprotein receptors of liver and macrophages. Glycoconjugate J. 12:1995;268-274.